Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 4pembrolizumab 2Radiotherapy 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Ipilimumab 2Cyclophosphamide 2tislelizumab 1teprotumumab 1pazopanib 1lenvatinib 1gallium citrate 1fludarabine phosphate 1fludarabine 1evolocumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1cabozantinib 1auricularum 1aldesleukin 1Spectrum Analysis 1Specimen Handling 1Pemetrexed 1Oxymorphone 1Oxycodone 1Nivolumab 1Morphine 1Levorphanol 1Lapatinib 1Hydromorphone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasm Metastasis × Gallium-68 × Clear all
NCT02391025 2023-06-18

Gallium-68 Citrate PET Used in Prostate Cancer

University of California, San Francisco

Phase EARLY_PHASE1 Completed
39 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡